A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00127179

Enrollment

600

Registered

2005-08-05

Start date

2004-01-01

Completion date

2005-07-25

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Brief summary

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Interventions

DRUGMK0906, finasteride / Duration of Treatment: 48 weeks

DRUGComparator: placebo / Duration of Treatment: 48 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

50 Years to 79 Years

Healthy volunteers

Inclusion criteria

* Patients with benign prostatic hyperplasia

Exclusion criteria

* Patients who are suspected to be suffering from prostatic cancer

Design outcomes

Primary

Measure	Time frame
Change from baseline in the International Prostate Symptom Score	—

Secondary

Measure	Time frame
Change from baseline in QOL - index	—
Change from baseline in maximum urinary flow rate, %	—
Change from baseline in Prostate volume	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026